APLT vs. CDMO, PBYI, GTHX, RIGL, PRTA, CPRX, RCKT, ZLAB, GLPG, and KROS
Should you be buying Applied Therapeutics stock or one of its competitors? The main competitors of Applied Therapeutics include Avid Bioservices (CDMO), Puma Biotechnology (PBYI), G1 Therapeutics (GTHX), Rigel Pharmaceuticals (RIGL), Prothena (PRTA), Catalyst Pharmaceuticals (CPRX), Rocket Pharmaceuticals (RCKT), Zai Lab (ZLAB), Galapagos (GLPG), and Keros Therapeutics (KROS). These companies are all part of the "pharmaceutical preparations" industry.
Avid Bioservices (NASDAQ:CDMO) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, community ranking, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.
In the previous week, Avid Bioservices and Avid Bioservices both had 5 articles in the media. Applied Therapeutics' average media sentiment score of 1.25 beat Avid Bioservices' score of 1.22 indicating that Avid Bioservices is being referred to more favorably in the media.
Avid Bioservices received 296 more outperform votes than Applied Therapeutics when rated by MarketBeat users. Likewise, 66.49% of users gave Avid Bioservices an outperform vote while only 56.35% of users gave Applied Therapeutics an outperform vote.
97.2% of Avid Bioservices shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 2.4% of Avid Bioservices shares are owned by company insiders. Comparatively, 8.6% of Applied Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Avid Bioservices currently has a consensus price target of $14.50, suggesting a potential upside of 79.23%. Applied Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 157.01%. Given Avid Bioservices' stronger consensus rating and higher possible upside, analysts plainly believe Applied Therapeutics is more favorable than Avid Bioservices.
Avid Bioservices has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500.
Applied Therapeutics has a net margin of 0.00% compared to Applied Therapeutics' net margin of -13.10%. Applied Therapeutics' return on equity of -8.78% beat Avid Bioservices' return on equity.
Avid Bioservices has higher revenue and earnings than Applied Therapeutics. Avid Bioservices is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Applied Therapeutics beats Avid Bioservices on 9 of the 17 factors compared between the two stocks.
Get Applied Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Applied Therapeutics Competitors List
Related Companies and Tools
